Roche has introduced the new CoaguChek INRange system self-testing device which helps patients to spend more time in therapeutic range with minimal training.


The Bluetooth enabled PT/INR home health device allows remote care programmes for anticoagulated patients.

It helps patients and their healthcare providers (HCPs) to have better control ontheir coagulation status and monitor Vitamin K Antagonist (VKA) therapy.

The system, which has been launched in countries accepting the CE Mark, allows patients to carry out a simple fingerstick and 60-second test themselves without disturbing the normal daily activities.

The hand-held home health device also allows patients to conveniently monitor PT/INR results with an user-interface.

It will also facilitate remote connectivity to their healthcare providers through Bluetooth technology.

Roche Diagnostics COO Roland Diggelmann said: "As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between HCPs and patients becomes even more important.

"This innovative technology continues the CoaguChek legacy of setting the standard in coagulation monitoring by providing high quality, convenient care, while optimising outcomes for patients."

The company also received FDA approval for its cytomegalovirus (CMV) test for use in hematopoietic stem cell transplant recipients.

The test standardizes CMV testing for both solid organ and hematopoietic stem cell transplant recipients. It can be used to monitor CMV treatment in all types of transplant patients.

Image: The administration and R&D buildings, Roche Diagnostics Ltd, Rotkreuz. Photo: courtesy of F. Hoffmann-La Roche Ltd.